The Fifth Circuit Just Exposed the FDA's PMTA System: What This Means

For years, flavored vape manufacturers have gotten the same answer from the FDA: denied. Not because their products were unsafe, but because of a standard nobody told them about until it was already too late to meet it.

On August 19, 2026, a federal court finally said something about that. In NicQuid, L.L.C. v. FDA, the Fifth Circuit vacated the FDA's denial of NicQuid's application and sent it back to the agency. In the process, the court called out exactly how the FDA built its flavored-vape enforcement system.

The Standard Nobody Was Told About

Here's the issue at the center of it all. To get a flavored e-liquid approved, the FDA has required manufacturers to prove their product helps adult smokers quit better than a tobacco-flavored one does, under a "comparative efficacy study." This might seem reasonable enough on paper. Except this standard was never published, never opened up for public comment, and never disclosed to anyone before they'd already sunk years and serious money into applications that didn't include it.

The court found the FDA built this requirement through two internal memos, skipping the public notice-and-comment process the law actually requires, then applied it retroactively to reject applications that had no way of knowing the goalposts had moved.

The Numbers Tell The Story

Out of more than six million flavored ENDS products submitted for review, the FDA approved 45. The court called that a "de facto ban." (1) This is a ban imposed without ever going through the process the law requires for creating one.

The opinion doesn't soften it, either. Manufacturers were "given no input into the closed-door development of the comparative efficacy rule," and "heard about the comparative-efficacy rule only when FDA denied their PMTAs with no ifs, ands, or buts." (1) The court's own words for it: "This is not a close call." (1)

What Happens Now

This isn't an instant win for flavored vapes across the board. The case goes back to the FDA, which can rework the standard, formally adopt it the right way this time, or take other steps in line with the ruling. What it can't do anymore is keep enforcing a rule nobody outside the agency ever saw.

Still, for an industry that's absorbed denial after denial under a standard it was never shown, this is the first real crack in the wall, with a court on record saying the process itself was built wrong, not just individual decisions.

Why It Matters

Seven manufacturers were party to this ruling, but the reasoning reaches further. Any company denied for lacking a comparative efficacy study it was never told to include now has a court decision saying that standard wasn't lawfully created in the first place. It's a real shift in a fight that had mostly gone the FDA's way until now.

We'll keep watching how the FDA responds, and what it means for the products on our shelves. But for now, this is an important milestone in protecting small businesses, independent vape brands, and consumers' right to choice.

References

(1) NicQuid, L.L.C. v. FDA, No. 24-60272, U.S. Court of Appeals for the Fifth Circuit, decided August 19, 2026. Full opinion: ca5.uscourts.gov/opinions/pub/24/24-60628-CV0.pdf